Clinical Evidence - Type 1 Diabetes

Clinical Evidence - Type 2 Diabetes

Introducing Dexcom's Digital Health Hub

Related Resources

Stelo: Personalizing Choices, Revolutionizing Glucose Health Presented by Patrick Welch, PharmD, BCACP

Premium Content

New Episodes Alert: Beyond the Bolus Podcast

alexa.stelzer — Mon, 30 Sep 2024 21:36:43 +0000

New Episodes Alert: Beyond the Bolus Podcast

10/01/2024

alexa.stelzer Mon, 09/30/2024 - 21:36

Explore Innovations in Diabetes Technology with Omnipod’s Beyond the Bolus Podcast

Discover the latest episodes of Omnipod’s Beyond the Bolus podcast! Featuring expert insights on Omnipod 5 and Dexcom G7 integration with Dr. Pablo Mora, and the future of Type 2 diabetes care with Dr. Viral Shah. Stay ahead with actionable advice and industry trends. Listen now to enhance your practice!

We are thrilled to announce the release of brand-new episodes of Beyond the Bolus, Omnipod’s podcast tailored for healthcare professionals. These episodes feature healthcare providers from a variety of backgrounds and specialties and explore the latest in diabetes technology, clinical data and more. Recent episodes include:

Omnipod 5 with Dexcom G7 Integration is Here!: Join Dr. Pablo Mora as he delves into the seamless integration of Omnipod 5 with Dexcom G7. Learn about the benefits of this integration and how it can simply diabetes management for your patients.
Unlock the Future of Type 2 Diabetes Care: Dr. Viral Shah shares his insights on the evolving landscape of type 2 diabetes care. Discover emerging trends, innovative treatments, and strategies to improve patient outcomes.

Whether you’re looking to stay ahead of the latest trends or seeking practical advice from industry leaders, these episodes are packed with valuable content to enhance your practice.

Stay connected, stay informed, and continue to provide the best care for your patients with Beyond the Bolus.

Listen here or using the player below.

Podcast

Diabetes Technology

Clinical Evidence - Type 2 Diabetes

Related Resources

Innovations for the Omnipod® 5 System: A Guide for Healthcare Providers

Podcast Episode 21: Clinical Accuracy in CGM and Why It Matters

Premium Content

Off

Podcast Episode 22: Revolutionizing Hospital Discharge Planning with CGM Technology

OlgaDalisay — Mon, 29 Jul 2024 20:07:29 +0000

Podcast Episode 22: Revolutionizing Hospital Discharge Planning with CGM Technology

07/29/2024

OlgaDalisay Mon, 07/29/2024 - 20:07

Guest Speaker: Dr. David Tulle

Real-time real talk is intended for healthcare professionals in the US.

In this episode of Real-Time Real Talk, host Cher Pastore speaks to guest, David Tulle who has worked for Dexcom for over 11 years, leading teams across the central Plains, in the mid south and US regions and is currently leading Dexcom’s hospital discharge program.

David’s focus is a new approach: integrating Continuous Glucose Monitoring (CGM) systems, such as Dexcom's, into hospital discharge plans for better diabetes management.

The conversation covers how the adoption of CGM systems, which provide real-time glucose data, is transforming transitional care strategies from hospital to home, and significantly improving patient outcomes.

Visit dexcomprovider.com to learn more about Dexcom's Hospital Discharge Program

Podcast

The Future of EHR and CGM Integration

Diabetes Technology

Podcasts

Yes

Related Resources

Podcast Episode 21: Clinical Accuracy in CGM and Why It Matters

Premium Content

Off

Real-World Use of Control-IQ Technology is Associated with a Lower Rate of Severe Hypoglycemia and DKA Than Historical Data

alexa.stelzer — Fri, 19 Apr 2024 17:38:27 +0000

Real-World Use of Control-IQ Technology is Associated with a Lower Rate of Severe Hypoglycemia and DKA Than Historical Data

04/26/2024

alexa.stelzer Fri, 04/19/2024 - 17:38

Results of the Control-IQ Observational (CLIO) Prospective Study

Research Spotlight

Graham R, Mueller L, Manning M, et al. Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study. Diabetes Technol Ther. 2024;26(1):24-32. doi:10.1089/dia.2023.0341

Background

Individuals on intensive insulin therapy (IIT) face an elevated risk of experiencing Severe Hypoglycemia (SH) and Diabetic Ketoacidosis (DKA). It is important to minimize the occurrence of these adverse events (AE), when possible. Automated Insulin Delivery (AID) systems may help reduce some of these events.

Purpose of Study

To assess the safety and effectiveness of the Tandem t:slim X2 insulin pump with Control-IQ technology in the real-world outpatient setting over 12 months of use.

Participant Demographics (n = 3157)

Single-arm, prospective, fully virtual, longitudinal study

T1D
At least 6 years old
Control IQ & Dexcom G6 for 12 months
Virtual check-in and data uploads

Study Outcomes Measured

The primary outcomes measured were:

Incidence rates of SH and SKA
Safety of the automatic population of CGM readings into the bolus calculator when Control-IQ technology was in use
Glycemic outcomes as a measure of efficacy of the system
Patient-reported satisfaction with and trust in the system, diabetes impact, and sleep quality of Control-IQ with Dexcom CGM technology users.

Main Outcomes

SH and DKA rates were lower for users of t:slim X2 with Control-IQ with Dexcom CGM compared to historical data^§ for both adults and children.
Average time in range was >70% for adults and >60% for children, both groups achieving international consensus guidelines¹
42% reported a decrease of diabetes impact on quality of life^†
25% increase in device satisfaction^‡in both participants transitioning to Control-IQ from a different pump system and for participants transitioning from MDI therapy

Key Takeaways for t:slim X2 with Control IQ and Dexcom CGM

Lower observed rates of adverse events occurred independent of baseline A1C or prior insulin delivery method²
Control-IQ with Dexcom CGM technology is associated with a lower rate of severe hypoglycemia (compared to historical data)²
The study also indicates a lower rate of diabetic ketoacidosis in individuals using Control-IQ with Dexcom CGM technology compared to historical data²
Reduction in diabetes burden was consistently reported²

*Mean (SD) AE rates per 100 patient years for study participants as self-reported on monthly surveys through 12 months of Control-IQ technology use, compared to historical rates

AE = Adverse events

† Diabetes Impact median score was 4.75 (3.25–6.0) at baseline and 2.75 (2.0–4.0) at 12 months (P < 0.01).

‡ DIDS Device Satisfaction median score increased from 7.29 (5.57–8.71) at baseline to 9.14 (8.29–9.71) at 12 months

§ Data from T1D Exchange Registry

References

Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi:10.2337/dci19-0028
Graham R, Mueller L, Manning M, et al. Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study. Diabetes Technol Ther. 2024;26(1):24-32. doi:10.1089/dia.2023.0341

Research Spotlight

Training Resources

dexcom-infographic-aid-clio-study-mat2235-v1 (4).pdf

Country

United States

Yes

Premium Content

Two Years with a Tubeless Automated Insulin Delivery System

alexa.stelzer — Fri, 19 Apr 2024 14:36:44 +0000

Two Years with a Tubeless Automated Insulin Delivery System

04/19/2024

alexa.stelzer Fri, 04/19/2024 - 14:36

A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes

Research Spotlight

Criego AB, Carlson AL, Brown SA, et al. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2024;26(1):11-23. doi:10.1089/dia.2023.0364

Background

Many people living with Type 1 diabetes (T1D) are struggling to achieve desired glycemic targets. Fortunately, Automated Insulin Delivery (AID) Systems have displayed promising outcomes in improving glycemic metrics.

Purpose of Study

To evaluate long-term safety and effectiveness of Omnipod® 5 AID system with Dexcom CGM in people with T1D during up to 2 years of use. This study is an extension of a 3-month outpatient pivotal clinical trial.

Participant Demographics (n = 224)

Extension phase of the single-arm, multicenter, pivotal trial.

T1D
A1C < 10%
Children (6-13.9 yo)
Adolescents/adults (14-70 yo)
Omnipod 5 & Dexcom G6 for 15 months
Sensor & glucose data collected for 2 years

Study Outcomes Measured

Primary effectiveness outcomes were:

Differences in A1C during the extension phase compared to baseline (before Omnipod 5)
Percentage of time in glucose target range² (TIR) during the extension phase compared to the standard therapy phase.

Primary safety outcomes were:

Incidence rates of severe hypoglycemia (SH) and diabetic ketoacidosis (DKA).

Main Outcomes

Both age cohorts saw significant improvements in glycemic outcomes, mainly A1C and TIR1, from baseline throughout the extension phase.

A1C decreased from 7.7% to 7.2% in peds, and 7.2% to 6.9% in adolescents/adults
TIR increased from 54.2% to 65.9% in peds, and 63.6% to 72.9% in adolescents/adults
No incidents of SH or DKA reported in adult cohort during the extension phase²
96% median time spent in automation mode² in both cohorts of participants using Omnipod 5 and Dexcom CGM

Adverse Events

7 SH events - all occurred in children and unrelated to the study device
1 DKA event - suspected infusion set failure in a child

Key Takeaways for Omnipod® 5 and Dexcom CGM

Effectiveness of Omnipod 5 system with Dexcom CGM† was maintained in both children and adults for up to 2 years of at home use²
Longest prospective follow-up study to date on the use of an AID system with Dexcom CGM²
Rates of AE remained low in both cohorts, and improvements in glycemic control was maintained, supporting long-term benefits from AID use

† This study was conducted using Omnipod 5 and Dexcom G6 Continuous Glucose Monitoring System

References

Criego AB, Carlson AL, Brown SA, et al. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2024;26(1):11-23. doi:10.1089/dia.2023.0364
Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi:10.2337/dci19-0028

Research Spotlight

Podcast Episode 14: A Dynamic Duo: Dexcom & Omnipod

Training Resources

Country

United States

Related Resources

Premium Content

Time in Tight Target Range as a New Way to Assess Glycemic Control

OlgaDalisay — Fri, 05 Apr 2024 17:12:19 +0000

Time in Tight Target Range as a New Way to Assess Glycemic Control

04/09/2024

OlgaDalisay Fri, 04/05/2024 - 17:12

Presented at ATTD 2024

With the widespread adoption of diabetes devices in the recent years there has been a change in the approach to assessing glycemic control metrics. In addition to A1C, many healthcare providers have turned to time in range as a new way to evaluate glycemic control.

Advances in diabetes care allow patients to monitor their glucose levels with great precision, and are leading experts to consider a new metric for glycemic control: time in tight range that has been defined as glucose levels between 70-140 mg/dL.

In this short ~17 min presentation Viral Shah, MD is going to provide a fresh outlook on time in range research. He will discuss:

Origins of time in range metric and its limitations
Overview of time in tight range
How TITR can help prevent chronic conditions
And where the future of the science lies

^{The information you see or hear at this event provides details about medical products which are not available in all countries, may have different indications, and/or have not received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing shown or stated herein should be construed as a solicitation, advertisement, or promotion of any product, or of an indication of any specific use for any product, which is not authorized by the laws and regulations of the country where you reside.}

^{The content may include the presenter’s own experience sharing and data – please do not record or distribute the presentation slides.}

Events

Expert Presentations

Expert Presentations - Type 1 Diabetes

ATTD 2024 Symposia: Making the Invisible Visible in Type 2 Diabetes

ATTD

Country

United States

Australia

Viral N. Shah, MD

Dr. Shah is a Professor of Medicine, Division of Endocrinology & Metabolism and Director of Diabetes Clinical Research at the IU Center for Diabetes and Metabolic diseases at Indiana University. His research focuses on improving glycemic control and reducing complications, with special interest in fracture prevention, in people with type 1 diabetes.

Related Resources

Premium Content

Systematic Review of Commercial Hybrid Closed-Loop AID Systems

OlgaDalisay — Tue, 27 Feb 2024 19:37:55 +0000

Systematic Review of Commercial Hybrid Closed-Loop AID Systems

02/27/2024

OlgaDalisay Tue, 02/27/2024 - 19:37

Despite advancements, many individuals with T1D struggle to maintain optimal glycemic control. Automated insulin delivery (AID) systems, particularly hybrid closed-loop (HCL) systems, aim to improve control and reduce burden by automating insulin delivery based on continuous glucose monitoring (CGM) data.

In this Research Spotlight we are highlighting a recent study:

Peacock, S., Frizelle, I. & Hussain, S. A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Ther 14, 839–855 (2023). https://doi.org/10.1007/ s13300-023-01394-5

The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Studies focusing on single-hormone commercial hybrid AID systems, involving participants with T1D, and reporting endpoints related to glycemic control were included.

The following endpoints were the main focus of the review:

Participants with T1D
A1c levels
Diabetic ketoacidosis (DKA) events
% of Time in Range (TIR) / Change in TIR
Incidents of severe hypoglycemia

Commercial HCL systems effectively improve TIR and glycemic control in T1D, with minimal risk of severe hypoglycemia.

Studies showed that HCL systems generally improved time in range (TIR) and glycemic control without increasing severe hypoglycemia. Psychosocial outcomes, such as quality of life and treatment satisfaction, were generally positive.

Results (Glycemic Outcomes)

Commercial HCL AID Systems are effective and can improve TIR³
Improvements in glycemic control were shown without increasing the incidence of severe hypoglycemia
Glycemic outcomes supported by real-world studies and randomized control trials (psychosocial endpoints analyzed separately - showing generally positive outcomes, but more data needed)

Research Spotlight

Training Materials - Downloads

Training Materials

EASD 2023: Real-Time CGM Clinical Outcomes – The 7-Year COMISAIR Data

Training Resources

dexcom-infographic-aid-peacock-study-mat-1197.pdf

Country

United States

Yes

Related Resources

Advancing Use and Access of AID Systems in the United Kingdom

Premium Content

Podcast Episode 19: Exercise, Type 1 Diabetes and CGM - Cutting Edge Insights from Recent Studies

OlgaDalisay — Wed, 14 Feb 2024 22:39:00 +0000

Podcast Episode 19: Exercise, Type 1 Diabetes and CGM - Cutting Edge Insights from Recent Studies

02/14/2024

OlgaDalisay Wed, 02/14/2024 - 22:39

Image shown does not include required overpatch. Please be sure to follow instructions for using the overpatch.

Guest Speaker: Dr. Dessi P. Zaharieva, PhD, CEP, CDCES

Real-time real talk is intended for healthcare professionals in the US.

In another episode of Real Time Real Talk, host Cher Pastore invites Dr. Dessi P. Zaharieva, to discuss all things diabetes. Dessi completed her PhD in Kinesiology & Health Science at York University under the supervision of leading diabetes researcher, Dr. Michael Riddell. She is currently working with Dr. David Maahs and the University of Stanford team to improve clinical outcomes in youth with type 1 diabetes.

Dessi Zaharieva's research focuses on effective strategies to reduce blood sugar fluctuations (i.e. hypoglycemia) during exercise and in recovery in individuals with type 1 diabetes.

Dessi has been living with type 1 diabetes for over 25 years and is also an award-winning high-level athlete within Brazilian Ju-Jitsu. She understands the challenges associated with exercise and blood glucose control and is very passionate about diabetes research, specifically the body’s response to different types of physical activity.

During the episode, Dessi runs through some clinical studies and interprets insights from them to provide practical and valuable advice on various types of exercise, insulin doses, and current glucose trends.

The speakers also explore the importance of continuous glucose monitoring in managing diabetes and the role played by patient-centered care. Finally, Dessi explores how technology advancements in health care have led to the development of tools that simplify guideline applications in practical real-time scenarios.

Learn how professional health care specialists like Dessi harness the knowledge gained over decades of research to ensure that it translates into ready-to-use strategies for those with diabetes.

Expert Presentations - Type 1 Diabetes

Clinical Evidence - Data Interpretation

Data Interpretation

Podcasts

Yes

Related Resources

Podcast Episode 11: "Don't Let Diabetes Define Your Life" - Conversations with Ariana Frayer

Systematic Review of Commercial Hybrid Closed-Loop AID Systems

Premium Content

Off

Podcast Episode 17: Unleashing the Power of Partnerships - Tandem Control IQ & Dexcom G7

OlgaDalisay — Mon, 18 Dec 2023 16:31:52 +0000

Podcast Episode 17: Unleashing the Power of Partnerships - Tandem Control IQ & Dexcom G7

12/20/2023

OlgaDalisay Mon, 12/18/2023 - 16:31

Guest Speakers: Jordan Pinkster, MD & Kristy Castilo, RN, CDCES

Real-time real talk is intended for healthcare professionals in the US.

In this episode of Real Time Real Talk, Cher Pastore interviewed Tandem’s Medical Director, Dr. Jordan Pinkster. Jordan is a pediatric endocrinologist by training, but has been involved in clinical trials and the development of automated insulin delivery (AID) products for many, many years. The second guest is Kristy Castillo, the clinical solutions manager at Tandem who is also a nurse, diabetes educator and lives with type one diabetes herself.

They'll discuss Tandem products including the t:slim X2 insulin pump and how it integrates with the Dexcom G6 and G7. Kristy also shares her first-hand experience of using AID.

See the preview below:

Podcast

Systematic Review of Commercial Hybrid Closed-Loop AID Systems

Podcasts

Yes

Related Resources

Premium Content

Off

EASD 2023: Diabetes Device Features Designed to Support Diabetes-Related Safety and Efficacy

OlgaDalisay — Thu, 02 Nov 2023 18:42:06 +0000

EASD 2023: Diabetes Device Features Designed to Support Diabetes-Related Safety and Efficacy

11/02/2023

OlgaDalisay Thu, 11/02/2023 - 18:42

In this 37 min presentation (includes Q&A) from EASD Annual Conference 2023, diabetes research expert Dr Battelino and Dr Hussain will discuss:

Cognitive decline and working memory complications associated with lower TIR
How CGM and AID systems can be used more effectively in various patient populations to improve outcomes

Dr Hussain will also talk about the new Dexcom G7 CGM system features, including:

The most device features designed to support diabetes related safety and efficacy (ULS, Delay 1st alert, Silence All)
Simple to start, easy to use and helps lower the burden of diabetes management
Exceptional accuracy for better informed treatment decisions

Expert Presentations

Expert Presentations - Type 1 Diabetes

Expert Presentations - Data Interpretation